Seroprevalence of Helicobacter pylori Infection in Cystic Fibrosis and Its Cross-Reactivity With Anti-Pseudomonas Antibodies

Israel, Noel R.; Khanna, Bhawna; Cutler, Alan F.; Perry, Marilyn; Caplan, Daniel B.; Weatherly, Mark; Gold, Benjamin D.

doi:10.1097/00005176-200004000-00015

Cited by 11 publications

(8 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This low incidence of peptic ulcer disease is not ascribable to an absence of upper gastrointestinal acid-peptic disease, since severe acid-peptic esophageal injury is common (59,60). Furthermore, CF patients, who are frequently endoscoped for upper gastrointestinal symptoms, have characteristic duodenal mucosal abnormalities (61), and can be infected with Helicobacter pylori (62). These observations further support our "intracellular bicarbonate" hypothesis: diminished apical bicarbonate exit with intact basolateral bicarbonate influx increases the steady state intracellular bicarbonate/pH i in the vulnerable duodenal epithelial cells in these patients, protecting them from injury due to luminal acid.…”

Section: Figuresupporting

confidence: 63%

Cellular bicarbonate protects rat duodenal mucosa from acid-induced injury

Akiba

Furukawa²,

Guth³

et al. 2001

J. Clin. Invest.

View full text Add to dashboard Cite

Section: Figuresupporting

confidence: 63%

Cellular bicarbonate protects rat duodenal mucosa from acid-induced injury

Akiba

Furukawa²,

Guth³

et al. 2001

J. Clin. Invest.

View full text Add to dashboard Cite

“…Other conditions that may cause confusion include cows' milk intolerance, 84 inflammatory bowel disease, 85,86 pancreatitis [87][88][89] (in PS patients), Helicobacter pylori infection, 90 celiac disease, 30,91 liver and gall bladder disease, 92 and intolerance of porcine enzyme preparations. 93 Persisting abdominal symptoms in patients on PERT in doses equivalent 10,000 IU lipase per kg per day whose malabsorption is not adequately controlled (coefficient of fat absorption <85%), requires consideration of patient adherance.…”

Section: Failure To Control Gastrointestinal Symptomsmentioning

confidence: 99%

Diagnosis and Treatment of Intestinal Malabsorption in Cystic Fibrosis

Littlewood

Wolfe

Conway

2005

Pediatric Pulmonology

102

View full text Add to dashboard Cite

Summary. Intestinal malabsorption is severe and of early onset in virtually all people who have cystic fibrosis. The main cause is deficiency of pancreatic enzymes. Bicarbonate deficiency, abnormal bile salts, mucosal transport problems, motility differences, and anatomical structural changes are other contributory factors. Effective treatment should allow a normal to high-fat diet to be taken, control symptoms, correct malabsorption, and achieve a normal nutritional state and growth. Appropriate pancreatic enzyme replacement therapy will achieve normal or near-normal absorption in most people with cystic fibrosis. Early identification and treatment of intestinal malabsorption is critical to achieving optimal nutritional status. The occurrence of fibrosing colonopathy in a few patients on very high doses of those enzymes which have the copolymer Eudragit L30 D55 in their covering resulted in guidelines in the UK to avoid doses equivalent to more than 10,000 IU lipase per kg per day, and also to avoid preparations containing this copolymer in children and adolescents. For patients not responding to 10,000 IU lipase per kg per day review of adherence to treatment, change of enzyme preparation, variation in time of administration, and reduction in gastric acid may improve absorption. The importance of early investigation to exclude other gastrointestinal disorders as a cause of the patient's symptoms, rather than merely increasing the dose of enzymes, is stressed. With modern pancreatic enzymes in doses up to or only slightly in excess of 10,000 IU lipase per kg per day, adequate control of gastrointestinal symptoms and absorption can be achieved, and a normal nutritional state and growth rate maintained in most people with cystic fibrosis.

show abstract

“…Only a small number of publications can be found addressing H. pylori and CF [84,85,86,87]. A study by Israel et al [85] is the only study addressing the prevalence of H. pylori infection in CF patients; it shows a lower prevalence than in similarly aged non-CF controls [87].…”

Section: Cystic Fibrosis and H Pylorimentioning

confidence: 99%

“…A study by Israel et al [85] is the only study addressing the prevalence of H. pylori infection in CF patients; it shows a lower prevalence than in similarly aged non-CF controls [87]. …”

Section: Cystic Fibrosis and H Pylorimentioning

confidence: 99%

See 1 more Smart Citation

<i>Helicobacter pylori</i> Infection and the Respiratory System: A Systematic Review of the Literature

Malfertheiner

Kandulski²,

Schreiber³

et al. 2011

Digestion

View full text Add to dashboard Cite

Background: Recent studies suggest an increased Helicobacter pylori prevalence in patients with various extradigestive inflammatory diseases. Similar to H. pylori infection, many respiratory diseases are characterized by chronic inflammation as well as increased immune response. Recent studies have evaluated the relation between various respiratory disorders and H. pylori infection. The aim of this systematic review was to scrutinize the relevant literature and the mechanisms that could underlie a role for H. pylori infection in respiratory diseases. Methods: Relevant literature regarding pathophysiological mechanisms and clinical epidemiology of H. pylori and different respiratory diseases has been systematically identified and analyzed by two independent reviewers according to a PubMed search for English language (until week 14, April 2010). Conclusions: At present, there is no definite proof of a causal relationship between H. pylori and respiratory diseases. Both H. pylori and various respiratory diseases are characterized by the release of proinflammatory cytokines and attraction of granulocytes as well as B- and T-cell-mediated response, though a pathophysiological association has not been proven. Neither the role of genetic predisposition of the host nor the presence of virulence factors nor the impact of H. pylori eradication have been studied in detail and definitely need further evaluation.

show abstract

Seroprevalence of Helicobacter pylori Infection in Cystic Fibrosis and Its Cross-Reactivity With Anti-Pseudomonas Antibodies

Cited by 11 publications

References 30 publications

Cellular bicarbonate protects rat duodenal mucosa from acid-induced injury

Cellular bicarbonate protects rat duodenal mucosa from acid-induced injury

Diagnosis and Treatment of Intestinal Malabsorption in Cystic Fibrosis

<i>Helicobacter pylori</i> Infection and the Respiratory System: A Systematic Review of the Literature

Contact Info

Product

Resources

About